Study on AUNIP as a Novel Tumor Marker for Cervical Cancer
Not yet recruiting
- Conditions
- Cervical Cancer
- Registration Number
- NCT06118463
- Lead Sponsor
- Lin Yuan
- Brief Summary
To detect the expression of AUNIP in cervical cancer serum, and to clarify its diagnostic and prognostic value.
- Detailed Description
Blood of all study participants of cervical cancer patients are collected to detect the expression of AUNIP, analyze the statistical correlation between the expression of cervical cancer AUNIP and clinicopathological parameters of patients, and preliminarily understand the expression of AUNIP in cervical cancer tumor tissues and its clinical diagnostic and progniostic value.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Female
- Target Recruitment
- 300
Inclusion Criteria
Study group inclusion criteria:
- Women aged 20-60
- There is a definite pathological diagnosis of cervical cancer
Healthy control group:
- Women aged 20-60
- No tumors in the uterus or other parts of the body
- No inflammatory disease
- Blood routine and blood biochemical tests are normal
Exclusion Criteria
Exclusion criteria of the study group:
- There are other lesions in the uterus and uterine adnexa
Exclusion criteria of healthy control group:
- Pregnant, lactating or menarche women
- Women who are undergoing human papillomavirus (HPV) vaccination
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AUNIP expression in serum through study completion, an average of 3 year Serum AUNIP expression is detected by ELISA kit. The results will be recorded seperately.
- Secondary Outcome Measures
Name Time Method